AstraZeneca may have included out-of-date drug data in information provided during U.S. trials of its COVID-19 vaccine, a regulator said late Monday, citing concerns from a monitoring board. 

The board "expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," a statement from the National Institute of Allergy and Infectious Diseases said. 

(With input from AFP)